Zymeworks/$ZYME
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zymeworks
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Ticker
$ZYME
Sector
Primary listing
Employees
273
Headquarters
Website
Zymeworks Metrics
BasicAdvanced
$1.3B
-
-$0.98
1.27
-
Price and volume
Market cap
$1.3B
Beta
1.27
52-week high
$19.50
52-week low
$9.03
Average daily volume
674K
Financial strength
Current ratio
7.691
Quick ratio
7.376
Long term debt to equity
4.512
Total debt to equity
5.584
Profitability
EBITDA (TTM)
-72.606
Gross margin (TTM)
-16.88%
Net profit margin (TTM)
-59.96%
Operating margin (TTM)
-67.32%
Effective tax rate (TTM)
-9.27%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
-11.19%
Return on equity (TTM)
-19.89%
Valuation
Price to revenue (TTM)
10.875
Price to book
3.97
Price to tangible book (TTM)
4.14
Price to free cash flow (TTM)
-32.395
Free cash flow yield (TTM)
-3.09%
Free cash flow per share (TTM)
-0.548
Growth
Revenue change (TTM)
95.94%
Earnings per share change (TTM)
-36.09%
3-year revenue growth (CAGR)
57.21%
3-year earnings per share growth (CAGR)
-39.24%
What the Analysts think about Zymeworks
Analyst ratings (Buy, Hold, Sell) for Zymeworks stock.
Bulls say / Bears say
Zymeworks reported Q2 2025 revenue of $48.7 million, up from $19.2 million a year earlier, and achieved net income of $2.3 million, reversing a prior-year loss (Reuters)
The company’s cash resources are projected to fund operations into the second half of 2027, supported by a strong cash balance of $333.4 million as of June 30, 2025 (Reuters)
Strategic partnerships delivered $20 million from BeOne and $7.5 million from BMS in Q2 milestone payments, validating Zymeworks’ collaboration model and providing non-dilutive funding (Reuters)
Q2 operating income was negative $0.674 million despite a headline net profit, indicating core operations remain unprofitable and reliant on non-recurring revenues (Reuters)
Operating expenses for Q2 2025 hit $49.4 million, consuming nearly all of the quarter’s revenue and highlighting a high cost base that may strain future margins (Reuters)
The net profit margin for Q2 stood at roughly 4.8%, underscoring that profitability is largely driven by one-off milestone payments rather than sustainable product or partnership revenues (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Zymeworks Financial Performance
Revenues and expenses
Zymeworks Earnings Performance
Company profitability
Zymeworks News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zymeworks stock?
Zymeworks (ZYME) has a market cap of $1.3B as of October 26, 2025.
What is the P/E ratio for Zymeworks stock?
The price to earnings (P/E) ratio for Zymeworks (ZYME) stock is 0 as of October 26, 2025.
Does Zymeworks stock pay dividends?
No, Zymeworks (ZYME) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next Zymeworks dividend payment date?
Zymeworks (ZYME) stock does not pay dividends to its shareholders.
What is the beta indicator for Zymeworks?
Zymeworks (ZYME) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.